Dr. McKay Discusses Immunotherapy Trials in RCC

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma (RCC).

Data presented at the 2017 ESMO Congress showed that the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival and response rates for patients with intermediate- and poor-risk disease, says McKay.

Currently, there are phase III trials exploring combinations of VEGF and immunotherapy in RCC, such as the combination of cabozantinib (Cabometyx) plus nivolumab with or without ipilimumab, and the combination of axitinib (Inlyta) and pembrolizumab (Keytruda).